A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine

The purpose of the study is to learn about safety and how the body processes the study medicine called Zavegepant (PF-07930207) in children with a history of migraine. This study helps understand how the medicine is changed and removed from the body after taking it. This study is seeking participants who: * Are children aged between 6 and less than 12 years old * Have had migraine for at least 6 months. * Weigh more than 15 kilograms All participants in this study will receive zavegepant as a nasal spray once (one spray into one nostril). The dose of the study medicine that each participant receives will depend on how much the participant weighs. The study will look at the experiences of the participants receiving the study medicine and collect data to better understand the possible benefits and unwanted effects of different doses of the study medicine. Participants will take part in this study for up to 10 weeks. During this time, they will have 3 study visits at the study clinic, and 2 follow-up phone calls.

NCT Number	NCT06995729
Lead Sponsor	Pfizer
Conditions	Acute Treatment of Migraine
Enrollment	16 participants
Start Date	2025-05-16
Primary Completion	2027-08-12 (estimated)
Study Completion	2027-08-12 (estimated)
Updated on ClinicalTrials.gov	2026-03-18